Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Briakinumab), ADCC Enhanced (CAT#: AFC-TAB-103)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.
Specific Inquiry
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Clone
- Briakinumab
- Applications
- FC, IP, ELISA, Neut, FuncS
- Conjugate
- Unconjugated
- Generic Name
- Briakinumab
- Related Disease
- Crohn's disease (CD)
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- Briakinumab; 339308-60-0; ABT-874; J695; BSF 415977; LU 415977; WAY-165772; A-796874.0; ABT-874; IL12B; interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40); NKSF2; interleukin-12 subunit beta; CLMF; CLMF2
Related Resources
Please refer to Briakinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Briakinumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Briakinumab"
Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab)Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.
See other products for "IL12+IL23"
Single-domain Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-1410-VHH | Recombinant Anti-Human IL12+IL23 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
Human Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-103 | Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | IgG1 - lambda |
| TAB-063 | Anti-Human IL12+IL23 Recombinant Antibody (Ustekinumab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
ADCC Enhanced Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-063 | Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Ustekinumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-103. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.